ANDERLECHT, Belgium--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With ...

MINNETONKA, Minn.--(BUSINESS WIRE)--Milla Pharmaceuticals Inc., an A.forall company, announced that its partner, Acella Pharmaceuticals LLC, has just commercialized its Abbreviated New Drug ...

Riverside portfolio company A.forall has signed a definitive agreement to sell its retail and hospital business unit to Abacus Medicine. Riverside originally invested in A.forall, formerly known as ...

WHITE BEAR LAKE, Minn., July 23, 2025--(BUSINESS WIRE)--Through its U.S. subsidiary, Milla Pharmaceuticals Inc., A.forall announced the direct commercialization and launch of Sodium Acetate Injection ...

A.forall, which is backed by The Riverside Company, has acquired Provepharm’s US generics portfolio. No financial terms were disclosed. The deal includes four FDA-approved and marketed sterile ...

MILAN — Forall SpA is beefing up its executive ranks. Maurizio Beffa was appointed chief commercial officer of the Italian men’s wear group, while Bryan La Vine was tapped as managing director of ...

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach ANDERLECHT, Belgium, September 09, 2025--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of ...

“After our rebranding into A.forall, uniting our teams and businesses under one single name that embodies our joint mission of making affordable medicines available to all, this fourth U.S. launch is ...